Egyptian hospitals uncover the hidden toll of a rare kidney disease
NCT ID NCT07218536
First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times
Summary
This study reviews medical records of 200 people diagnosed with a rare blood and kidney disease called aHUS in Egyptian hospitals. Researchers want to learn about patient symptoms, treatments, and long-term health to help doctors diagnose and manage the disease better. No new treatments are tested; the goal is to gather information to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
200 people
The number who actually took part.
- Started
-
Oct 2025
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed with TMA between 01-Jan-2010 and 31-Dec-2023 regardless of administered treatment. Medical records of all patients fulfilling the eligibility criteria will be collected.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patients aged one month or older who have been diagnosed with TMA between 01-Jan-2010 and 31-Dec-2023. Exclusion Criteria: * None. All records of patients with TMA will be screened for aHUS diagnosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atypical hemolytic uremic syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Alexandria, Egypt
-
Research Site
Asyut, Egypt
-
Research Site
Cairo, Egypt
-
Research Site
New Cairo, Egypt
-
Research Site
Tanta, Egypt
-
Research Site
Zagazig, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can aHUS patients safely stop eculizumab? algorithm put to the test
- New hope for aHUS patients: Long-Term iptacopan study launches
- Skin biopsies could unlock hidden genetic diagnoses
- Real-World study tracks Ravulizumab's impact on rare kidney disease
- New pill shows promise for rare blood disorder aHUS
- New drug ravulizumab aims to control rare blood disorder aHUS